Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of GSK716155 in Type 2 Diabetes
NCT00354536Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2006
- Primary completion
- Sep 2006
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of albiglutide in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Feb 2006; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00354536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354536.